CXCL8 and melanoma: The anti-IL-8 monoclonal antibody, BMS-986253, combined with nivolumab showed preliminary activity in melanoma progressing on checkpoint inhibitors, as reported in a phase I/II trial presented at ESMO Immuno-Oncology Congress 2022 [80].